- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04748861
CYCLE-AD (CYcling to Cease or Limit the Effects of Alzheimer's Disease) (CYCLE-AD)
September 11, 2023 updated by: The Cleveland Clinic
CYCLE-AD: Randomized Controlled Trial to Assess the Efficacy of Indoor Cycling in Slowing Disease Progression in Healthy Older Persons at Genetic Risk for Alzheimer's Disease
The overall goal of the CYCLE-AD trial is to determine the role of long-term, high intensity exercise in slowing or delaying the onset of cognitive and AD-related brain changes in e4 carriers.
Successful translation and demonstration of the effectiveness of a scalable home-based exercise intervention capable of slowing or delaying disease onset will transform AD treatment, improve patient outcomes and quality of life, and reduce health care costs.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
The apolipoprotein E epsilon 4 (APOE e4) allele is the most important genetic risk factor for late onset Alzheimer's disease (AD).
A recent review by the World Health Organization highlighted the potential protective role of physical activity and exercise against cognitive decline, all-cause dementia, AD, and vascular dementia in healthy individuals.
In an 18-month longitudinal observational study, investigators showed that sedentary e4 carriers experience significant declines in episodic memory and hippocampal volume compared to 4 carriers who engaged in moderate PA.
Importantly, among 4 non-carriers, no significant longitudinal changes in cognition and brain imaging were observed whether the non-carriers were sedentary or engaged in moderate PA, suggesting that PA has a specific neuroprotective role in delaying the progression of AD in e4 carriers.
Based on the results, a pragmatic, randomized controlled trial with blinded clinical and imaging outcomes is proposed to determine the impact of a home based, high intensity exercise intervention in healthy, cognitively intact e4 carriers between the ages of 65 and 80 years.
The CYCLE-AD (CYcling to Cease or Limit the Effects of Alzheimer's Disease) trial will recruit otherwise healthy sedentary carriers randomized to one of two groups (n=75 each): 1) an Indoor Cycling (IC) group that participates in high-intensity interval training (HIIT; 60-90% of heart rate reserve) in their home via the commercially available Peloton® cycling system or 2) a Usual and Customary Care (UCC) group, in which participants engage in their habitual level of PA.
Investigators hypothesize that an 18-month high-intensity aerobic exercise regimen will slow AD-related disease progression in sedentary elders at genetic risk for AD.
Participants in the intervention group will engage in exercise 3x/week (minimum 90 minutes/week) for 18 months.
Primary outcome measures, obtained at study entry and at 18 months, will include comprehensive cognitive testing and brain MR imaging to assess disease progression and a comprehensive PA/fitness assessment to measure the degree of change in physical fitness due to high intensity aerobic exercise.
Study Type
Interventional
Enrollment (Estimated)
150
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Stephen Rao, PhD
- Phone Number: 216-444-1025
- Email: raos2@ccf.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
Contact:
- Stephen Rao, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years to 80 years (Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy elders, ages 65-80 years, inclusive
- No cognitive impairment based on screening examination
- APOE ε4 genotype
- Inactive; defined as exercising less than 3x per week at moderate-vigorous intensity
- Fluent in English (a requirement for neurocognitive testing)
- Does not plan to travel for more than 2 consecutive weeks over the course of the study
- Demonstrate ability to safely mount and dismount Peloton stationary cycle
- In-home Wi-Fi (Peloton system requires Wi-Fi to transmit exercise data)
- Medical clearance by the study doctor to participate in exercise program
- Participant must meet Peloton height and weight safety requirements
Exclusion Criteria:
- Any significant neurologic disease, including dementia, mild cognitive impairment, Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, stroke, multiple sclerosis, or history of significant head trauma with a reported loss of consciousness for greater than 30 minutes.
- Significant medical illnesses/conditions that is unstable and/or uncontrolled (lung or kidney disease, cancer).
- History of schizophrenia or bipolar disorder.
- Major Depression within the past year.
- History of alcohol or substance abuse or dependence within the past 2 years.
- Current use of Alzheimer's disease medications, including cholinesterase inhibitors and memantine.
- Any unstable or severe cardiovascular disease or asthmatic condition.
- History of imaging confirmed transient ischemic attack or a score of >4 on the modified Hachinski ischemic scale.
- Significant abnormalities in laboratory blood tests that is considered to be a contraindication to exercise.
- Exclusion criteria specific to MR scanning (weight inappropriate for height, ferrous objects within the body, pregnancy, and a history of claustrophobia).
- A musculoskeletal issue (arthritis, osteoporosis, back problem) that would limit one's ability to engage in exercise
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Indoor Cycling (IC)
Participants will engage in high-intensity interval training (HIIT; 60-90% of heart rate reserve) in their home via the commercially available Peloton® cycling system or 2) 3x/week (minimum 90 minutes/week) for 18 months.
|
Participants will ride a Peloton bike 3x/week for 18 months.
|
No Intervention: Usual and Customary Care (UCC)
Participants engage in their habitual level of physical activity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rey Auditory Verbal Learning Test Total Recall Trials 1-5 (RAVLT1-5).
Time Frame: 18 months
|
Determine the effects of an IC intervention on cognitive functioning
|
18 months
|
Total Hippocampal Volume (THV)
Time Frame: 18 months
|
Determine the effects of an IC intervention on MR brain imaging
|
18 months
|
V̇O2max
Time Frame: 18 months
|
Determine the effects of an IC intervention on PA/fitness testing
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Stephen Rao, PhD, The Cleveland Clinic
- Principal Investigator: Jay Alberts, PhD, The Cleveland Clinic
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 20, 2021
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
February 3, 2021
First Submitted That Met QC Criteria
February 9, 2021
First Posted (Actual)
February 10, 2021
Study Record Updates
Last Update Posted (Actual)
September 13, 2023
Last Update Submitted That Met QC Criteria
September 11, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-1198
- 1R01AG070736-01 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Normal Cognition
-
Peking University Sixth HospitalRecruitingCerebral Blood Flow | Cognitive Change | Cardiovascular Risk Factors | fMRI | Normal CognitionChina
-
BiogenApple Inc.TerminatedMild Cognitive Impairment | Normal AgingUnited States
-
National Research Center for Rehabilitation Technical...CompletedCognition Disorders | Motor Disorders | Normal VolunteersChina
-
Huashan HospitalSchool of Public Health,Fudan University; Medicine-Mental Health Center of... and other collaboratorsActive, not recruitingMild Cognitive Impairment | The Cognitive Normal ElderlyChina
-
University of Roma La SapienzaAUSL LatinaNot yet recruitingCognitive Impairment | Normal Pressure HydrocephalusItaly
-
Chang Gung Memorial HospitalNot yet recruitingMild Cognitive Impairment | Subjective Cognitive Decline | Cognitively-normalTaiwan
-
University of California, San FranciscoNational Institute on Aging (NIA)CompletedCognitive Impairment | Aging | Mild Cognitive Impairment | Cognitive Training | Cognitive Aging | Cognitively Normal Older AdultsUnited States
-
Umeå UniversityCompletedIdiopathic Normal Pressure Hydrocephalus
Clinical Trials on Indoor Cycling (IC)
-
University of North Carolina, Chapel HillCompletedDepression | Stress, Psychological | AnxietyUnited States
-
Paracelsus Medical UniversityCompleted
-
Poznan University of Physical EducationPoznan University of Medical SciencesCompletedHypertension | Obesity | Dyslipidemias | Type 2 Diabetes | Endothelial DysfunctionPoland
-
Azienda Usl di BolognaRecruitingLightning Strategies on Health | Circadian Rhythms Photoentrainment | Photoentrainment and Sleep | DLMOItaly
-
London School of Hygiene and Tropical MedicineMedical Research Council; University of Witwatersrand, South Africa; National... and other collaboratorsCompleted
-
Klein Buendel, Inc.National Cancer Institute (NCI); University of Connecticut; Colorado State University and other collaboratorsCompleted
-
University of LeicesterWellcome Trust; MedtronicCompletedHyperglycemia | Diabetes Mellitus, Type 2 | Glucose IntoleranceUnited Kingdom
-
Hong Kong Baptist UniversityRecruitingDepressive SymptomsHong Kong
-
Lithuanian University of Health SciencesRecruitingCoronary Artery Disease | Cardiac Rehabilitation | Cognitive Function 1, Social | Stress Reaction | Nature, HumanLithuania
-
Technical University of MunichMax-Planck Institute for Biological CyberneticsRecruitingLight SensitivityGermany